12.02.2016 • NewsDede WillamsPfizerbusiness

Leadership Team Named for Pfizer-Allergan

As announced earlier, current Allergan CEO Brent Saunders is the new...
As announced earlier, current Allergan CEO Brent Saunders is the new company’s designated president and CEO. He will have responsibility for the oversight of Pfizer and Allergan's combined commercial businesses, manufacturing and strategy functions.

US pharmaceutical giant Pfizer has unveiled the executive leadership team foreseen for its envisaged $160 million merger with Allergan and the move of the company’s official headquarters to Ireland. Plans for the deal structured as a takeover of Pfizer by Ireland-domiciled Allergan, and scheduled to close in the first half of 2016, were announced in late November 2015. Both companies are US-owned.

When making the leadership announcement, Pfizer chairman and CEO Ian Read noted that the combined company, which will trade under the name Pfizer, is being designed to facilitate a break-up into separate companies. Any decision about a split would be made “no later than the end of 2018,” he said.

As announced earlier, current Allergan CEO Brent Saunders is the new company’s designated president and CEO. He will have responsibility for the oversight of Pfizer and Allergan's combined commercial businesses, manufacturing and strategy functions.

When the new Pfizer takes on its final shape, it will be managed, as the old Pfizer was, through two distinct businesses: an Innovative Products business and an Established Products business.

The Innovative Products business will have two operating segments, Global Innovative Pharmaceutical (GIP) and the Global Specialty and Consumer Brands.

Pfizer’s existing Vaccines and Oncology businesses (VOC) will be merged into the GIP business, with Albert Bourla, currently group president VOC, as group president. Geno Germano, currently group president of Pfizer’s Global Innovative Pharma Business, will leave the company upon closing of the deal.

The new Pfizer’s operating segment Global Specialty and Consumer Brands will be comprised of the former Pfizer's Consumer Healthcare unit and Allergan's ophthalmology and aesthetics businesses, along with Botox Therapeutic and Cosmetic. It will be headed as president by Bill Meury, currently executive vice president and president Branded Pharma at Allergan.

The Established Products business will continue to be led by Pfizer’s John Young. It will consist of the Global Established Pharmaceutical segment and include all legacy Hospira commercial operations.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.